

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Vital Innovations Holdings Limited**  
**維太創科控股有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
(Stock Code: 6133)

**PROFIT WARNING**

This announcement is made by Vital Innovations Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) hereby inform the shareholders and potential investors of the Company that, based on the information currently available to the Board and the preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2019 (the “**2019 Interim Period**”), it is currently expected that the Group may record a net profit of approximately RMB0.5 million for the 2019 Interim Period, as compared to a net profit of RMB9.8 million for the six months ended 30 June 2018 (“**2018 Interim Period**”). Based on information currently available to the Board, such decrease in net profit was primarily attributable to (i) the absence of an one-off reversal of impairment recognised on trade receivables of approximately RMB5.6 million for the 2018 Interim Period; (ii) a drop in turnover and a decrease in gross profit from approximately RMB7 million for the 2018 Interim Period to approximately RMB4.5 million for the 2019 Interim Period due to the relatively less active market and strong price competition; and (iii) the exchange losses of approximately RMB800,000 for the 2019 Interim Period as compared to an exchange gain of RMB 441,000 for the 2018 Interim Period due to the fluctuation of RMB against HKD and USD.

It should be noted that the Company is still in the process of finalising the interim results of the Group for the 2019 Interim Period. The information contained in this announcement is only based on preliminary assessments made by the Board with reference to the information currently available, which has not been reviewed by the Company’s auditors and the audit committee of the Company and may be subject to changes. Shareholders and potential investors of the Company are therefore advised to read carefully the interim results announcement of the Company for the 2019 Interim Period to be published on 28 August 2019.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Vital Innovations Holdings Limited**  
**Rong Xiuli**  
*Chairperson*

Hong Kong, 23 August 2019

*As at the date of this announcement, the executive directors of the Company are Ms. Rong Xiuli, Mr. Rong Shengli, Mr. Yin Xuquan, Mr. Tang Shun Lam and Mr. Wong Ho Chun; and the independent non-executive directors of the Company are Mr. Hon Kwok Ping Lawrence, Mr. Lam Yiu Kin and Mr. Han Xiaojing.*